MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-19-2026
Akari Therapeutics, Plc Long Term Debt Current 2011-2026 | AKTX
Annual Long Term Debt Current Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 4.6 M | 4.44 M | 721 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 M | 721 K | 3.25 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
1.83 M | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | China |
 |
BioNTech SE
BNTX
|
45 M | $ 92.14 | 1.33 % | $ 22.3 B | Germany |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
521 K | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
235 K | $ 0.72 | -0.37 % | $ 32.9 M | Israel |
 |
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | Germany |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
65 K | $ 32.59 | -6.89 % | $ 877 M | USA |
|
Forte Biosciences
FBRX
|
416 K | $ 21.59 | -1.86 % | $ 280 M | USA |
 |
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
320 K | - | - | $ 13.1 M | Canada |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
2.66 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
2.05 M | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | Canada |
 |
InflaRx N.V.
IFRX
|
257 K | $ 2.61 | 5.67 % | $ 176 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
1.4 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
4.16 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 20.86 | -0.71 % | $ 2.65 B | USA |